venBio Select Advisor LLC Purchases 62,500 Shares of Global Blood Therapeutics Inc (GBT)

venBio Select Advisor LLC grew its position in shares of Global Blood Therapeutics Inc (NASDAQ:GBT) by 21.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 350,000 shares of the company’s stock after acquiring an additional 62,500 shares during the quarter. Global Blood Therapeutics accounts for 0.9% of venBio Select Advisor LLC’s holdings, making the stock its 22nd biggest position. venBio Select Advisor LLC owned approximately 0.67% of Global Blood Therapeutics worth $14,368,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in GBT. Lindbrook Capital LLC bought a new stake in Global Blood Therapeutics in the 4th quarter valued at $55,000. Bank of Montreal Can raised its stake in Global Blood Therapeutics by 61.9% in the 4th quarter. Bank of Montreal Can now owns 1,582 shares of the company’s stock valued at $65,000 after acquiring an additional 605 shares during the period. Strs Ohio bought a new stake in Global Blood Therapeutics in the 4th quarter valued at $65,000. Focused Wealth Management Inc bought a new stake in Global Blood Therapeutics in the 3rd quarter valued at $104,000. Finally, PNC Financial Services Group Inc. raised its stake in Global Blood Therapeutics by 740.3% in the 3rd quarter. PNC Financial Services Group Inc. now owns 4,353 shares of the company’s stock valued at $165,000 after acquiring an additional 3,835 shares during the period.

A number of equities research analysts recently weighed in on GBT shares. William Blair restated a “buy” rating on shares of Global Blood Therapeutics in a research note on Wednesday, January 30th. ValuEngine cut Global Blood Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, January 10th. HC Wainwright set a $150.00 price objective on Global Blood Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, December 4th. Cantor Fitzgerald set a $96.00 price objective on Global Blood Therapeutics and gave the stock a “buy” rating in a research report on Monday, December 3rd. Finally, Oppenheimer set a $82.00 price objective on Global Blood Therapeutics and gave the stock a “buy” rating in a research report on Monday, December 3rd. Three investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Global Blood Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $85.79.



NASDAQ:GBT traded up $0.07 during trading hours on Friday, hitting $52.60. The company’s stock had a trading volume of 5,374 shares, compared to its average volume of 672,418. The firm has a market capitalization of $2.96 billion, a PE ratio of -15.41 and a beta of 2.13. Global Blood Therapeutics Inc has a twelve month low of $30.15 and a twelve month high of $55.20.

Global Blood Therapeutics (NASDAQ:GBT) last released its quarterly earnings data on Wednesday, February 27th. The company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.04). During the same quarter last year, the business earned ($0.95) earnings per share. As a group, sell-side analysts anticipate that Global Blood Therapeutics Inc will post -3.89 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “venBio Select Advisor LLC Purchases 62,500 Shares of Global Blood Therapeutics Inc (GBT)” was originally posted by Dakota Financial News and is the property of of Dakota Financial News. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://dakotafinancialnews.com/2019/03/15/venbio-select-advisor-llc-purchases-62500-shares-of-global-blood-therapeutics-inc-gbt.html.

Global Blood Therapeutics Company Profile

Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.

Featured Article: How to Track your Portfolio in Google Finance

Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.